Company Profile

Ultradian Diagnostics LLC
Profile last edited on: 7/27/2018      CAGE: 4U8R1      UEI: VAQFB96DV593

Business Identifier: Wireless technologies: on-patient biosensors for monitoring chronic disease
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5 University Place Suite A324
Rensselaer, NY 12144
   (518) 618-0046
Location: Single
Congr. District: 20
County: Rensselaer

Public Profile

Ultradian Diagnostics is a clinical stage medical device company developing a suite of advanced, continuous, wireless biosensor technologies for on-patient monitoring and management of chronic disease. Ultradian's initial focus is the development of a next generation, calibration-free, minimally invasive continuous glucose monitoring (CGM) system, called Biologue, that will fundamentally alter existing paradigms for managing diabetes. The inherent flexibility of Biologue serves as a platform for an expanded menu of minimally invasive and skin-contact diagnostic tests and therapeutic modalities to monitor and manage a variety of chronic disease conditions. Ultradian Diagnostics has entered into a strategic partnership with a lage electronics manufacturer to integrate our Gen 2 CGM electronics into a single chip solutoion. This will simplify our assembly process and eventually lead to a low-cost, totally disposable CGM that can be integrated with an insulin pump to create a closed-loop system. This new technology will also advance the minimally and a non-invasive diagnostic capabilities of the Biologue platform into remote patient monitoring, sports medicine, and military applications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $1,459,257
Project Title: Continuous Monitoring of Glycemic Oscillations in Interstitial Fluid
2009 1 NIH $146,278
Project Title: In Vitro Feasibility Of A Rapid Response Continuous Glucose Sensor

Key People / Management

  Gib Conover -- President & COO

  John P Willis -- Chairman and Chief Executive Officer

  Andrew Armenia -- Project Manager

  Chris Gesswein -- VP Business Development

  Ted Minior -- VP Manufacturing

Company News

There are no news available.